House Bill 1495, introduced in Maryland on February 12, 2025, aims to enhance health insurance coverage for ovarian cancer screenings. The bill mandates that certain insurers, nonprofit health service plans, and health maintenance organizations provide coverage for preventive screenings for individuals over a specified age. Notably, it prohibits these entities from imposing any copayment, coinsurance, or deductible requirements on this coverage.

The primary objective of House Bill 1495 is to improve access to early detection of ovarian cancer, a disease that often goes undiagnosed until advanced stages, leading to lower survival rates. By eliminating out-of-pocket costs for screenings, the bill seeks to encourage more individuals to undergo these potentially life-saving tests.

The bill has sparked discussions among lawmakers and health advocates regarding its implications for public health and insurance practices. Supporters argue that the legislation could significantly increase early detection rates and ultimately save lives, while opponents raise concerns about the financial impact on insurance providers and the potential for increased premiums.

As the bill progresses through the legislative process, its economic implications are under scrutiny. Experts suggest that while the upfront costs for insurers may rise due to mandated coverage, the long-term benefits of early detection could lead to reduced treatment costs and improved health outcomes.

House Bill 1495 represents a significant step toward addressing women's health issues in Maryland. If passed, it could set a precedent for similar legislation in other states, reflecting a growing recognition of the importance of preventive health measures. The bill is currently assigned to the Rules and Executive Nominations Committee, where further discussions and potential amendments will take place.